51³Ô¹ÏÍø

Tag - alzheimer's

 
Menu
Search
 
July 25, 2026
 

Home Delivery
Subscribe for more access

ALZHEIMER'S

Japan Times
WORLD / Science & Health
Jul 17, 2023
Alzheimer¡¯s diagnosis revamp embraces rating scale similar to cancer
New guidelines would replace terminology such as mild, moderate and severe, instead using a numerical system related to disease progression.
Japan Times
BUSINESS / Companies
Jul 11, 2023
Eisai appoints CEO¡¯s son to lead global Alzheimer drug program
Eisai¡¯s former global Alzheimer drug program officer, who led the push for U.S. approval of breakthrough medicine Leqembi, will retire at the end of the month.
Japan Times
WORLD / Science & Health
Jul 7, 2023
Eisai Alzheimer¡¯s drug gets full U.S. approval, widening access to the therapy
The broader clearance from the Food and Drug Administration marks a milestone for treatment of the dementia that afflicts some 6 million Americans.
Japan Times
51³Ô¹ÏÍø / Science & Health / FOCUS
Jul 4, 2023
Expectations grow for Alzheimer¡¯s drug in Japan, but hurdles remain
Lecanemab could be approved in the country as early as fall, but more specialist doctors and a patient screening system would be needed for widespread use.
Japan Times
COMMENTARY / World
Jul 3, 2023
Can we cure dementia before it starts?
Octogenarian and biologist Leroy Hood is trying to make the Elizabeth Holmes-ian dream of preventive medicine come true.
Japan Times
WORLD / Science & Health
Jun 19, 2023
New Eisai and Biogen Alzheimer drug faces hurdles in Europe
Some doctors said its effect on the disease may not be clinically meaningful enough when weighed against the risk of brain swelling, its likely high price.
Japan Times
BUSINESS
Jun 1, 2023
Obesity and Alzheimer¡¯s news makes Eli Lilly world¡¯s most valuable drugmaker
An 8.5% gain in May for Eli Lilly lifted its shares to a record high, while displaced Johnson & Johnson slumped 5.3% during the month.
Japan Times
COMMENTARY / World
May 17, 2023
A breakthrough on Alzheimer¡¯s is closer than ever
Promising data could open the door to insurance coverage for expensive new Alzheimer¡¯s drugs, bringing them closer to patients.
Japan Times
WORLD / Science & Health / FOCUS
May 9, 2023
Drugs developed to treat diabetes may offer new approach against Alzheimer¡¯s
Experts hope that by improving glucose metabolism, and tamping down inflammation in the entire body, they can slow progression of diseases like Alzheimer¡¯s and Parkinson¡¯s.
Japan Times
WORLD / Science & Health
May 5, 2023
Experimental Alzheimer¡¯s drug slowed disease by 35% in trial, Eli Lilly reports
The results provide what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.
Japan Times
51³Ô¹ÏÍø
Jan 30, 2023
Priority review status given to Alzheimer¡¯s drug developed by Eisai and Biogen
The companies said priority review in Japan is granted to new medicines recognized as having high medical utility for serious diseases.
Japan Times
BUSINESS / Markets
Jan 10, 2023
Eisai shares jump after FDA approves Alzheimer¡¯s drug lecanemab
The drug, to be sold under the brand name Leqembi, was approved by the Food and Drug Administration under an accelerated pathway.
Japan Times
BUSINESS / Companies
Dec 28, 2022
Tokyo firm targets blood tests for Alzheimer¡¯s in wake of therapy breakthrough
Fujirebio Holding is boosting its lineup of reagents used to detect Alzheimer¡¯s biomarkers in blood tests.
Japan Times
51³Ô¹ÏÍø / Science & Health
Dec 22, 2022
Japan approves blood test to detect Alzheimer¡¯s
Japan has approved one of the world¡¯s first blood test kits to detect signs of Alzheimer¡¯s disease, paving way for a simpler and speedier diagnosis of the ailment for which a therapy is on the horizon.
Japan Times
BUSINESS
Nov 30, 2022
Eisai Alzheimer¡¯s drug sparks debate over benefits as risks like brain bleeding emerge
The key issue is whether the modest slowing of the disease is meaningful to individual patients and their families, especially in light of the potential side effects.
BUSINESS / Markets
Nov 29, 2022
Eisai and Biogen plunge after report of second death in Alzheimer¡¯s trial
The case involved a 65-year-old woman who died of a massive brain hemorrhage after suffering a stroke and a type of brain swelling and bleeding in an Eisai trial, a report said.
Japan Times
COMMENTARY / World
Oct 4, 2022
New Alzheimer¡¯s drug from Biogen and Eisai is just the beginning
A successful late-stage trial of lecanemab gives researchers promising new avenues for tackling this hard-to-beat disease.
Japan Times
WORLD / Science & Health / ANALYSIS
Sep 30, 2022
Eisai drug¡¯s trial success raises hope for Alzheimer¡¯s prevention
Scientists have already begun to debate whether the benefit of the drug is robust enough, but to many researchers, the findings suggest that preventing decline altogether is possible.
Japan Times
51³Ô¹ÏÍø / Science & Health
Sep 28, 2022
Alzheimer¡¯s progression slowed by drug in major trial
The drug slowed cognitive decline in people with early Alzheimer¡¯s by 27% over 18 months when compared with a placebo using a common rating scale.
Japan Times
BUSINESS / Companies
Jul 6, 2022
Eisai says Alzheimer¡¯s drug will get priority review in U.S.
Under the accelerated approval pathway, drugs can be approved based on their ability to remove amyloid, a hallmark of the disease, from the brain.
Japan weighs regulating Pokemon cards amid trading mania
A Pokemon event is held in Jakarta on July 11
Head of Swiss euthanasia firm dies after collapsing while ascending Mount Fuji
Around 200,000 people typically scale the 3,776 meter Mount Fuji each year.
Indian brothers make manga debut in Japan
Two Indian brothers made their manga debut in Japan with "Kung Fu Kung Fool" ¡ª an action-comedy series that follows the adventures of a notorious thief and a young boy.
Japan scientists identify clusters of protein believed to trigger Alzheimer¡¯s disease
A team of researchers said they found a ¡°seed¡± that accelerates the amyloid beta accumulation process in the brain, naming it ¡°Peak 1 amyloid beta,¡± as seen in a mouse's brain.
A perfect storm: Kaze Fujii fans flock to Fuji Rock
Okayama-born singer-songwriter Kaze Fujii has carved out a distinctive place in Japanese pop since his major-label debut in 2019.
The sci-fi sensibilities of electronic trio Black Boboi
Black Boboi was formed in 2018 when solo artists Julia Shortreed, Utena Kobayashi and Ermhoi came together under Kobayashi¡¯s newly founded label, Bindividual.
A perfect storm: Kaze Fujii fans flock to Fuji Rock
Okayama-born singer-songwriter Kaze Fujii has carved out a distinctive place in Japanese pop since his major-label debut in 2019.
Can Japanese comedy get laughs in English? Yoshimoto Kogyo lets the jokes rip
Wes-P has millions of followers and his viral clips made him recognizable out of Japan.
The 180-day locals: Life on Japan¡¯s digital nomad visa
Christopher Flinn works remotely from Tokyo earlier this month. Japan issued 646 digital nomad visas in 2025, but tourism officials are hoping to increase that figure in the coming years, with Japan's relatively cheap cost of living and the weak yen seen as potential draws for young professionals.
Japan reveals hint of new defense spending target in fiscal blueprint
The Self-Defense Forces' Type 16 mobile combat vehicle fires during a joint live-fire drill with U.S. Marines as part of the annual Resolute Dragon exercises in Yufu, Oita Prefecture, on June 28.

Podcast

One of the many entrances to the Kabukicho neighborhood in Tokyo¡¯s Shinjuku Ward.
Kabukicho: Tokyo¡¯s ¡®stadium of desire¡¯

Longform

For many people, utility poles and power lines have become such a familiar part of Japan¡¯s landscape that they often go unnoticed.
Why Japan¡¯s utility poles won¡¯t be disappearing anytime soon
By Alex K.T. Martin

SUSTAINABLE 51³Ô¹ÏÍø

SPECIAL SUPPLEMENTS note

SUPPLEMENTS BINDER